Region Stockholm – SLSO

At Region Stockholm – SLSO the focus is on developing new treatments for diseases of the nervous system, aiming to slow disease progression and improve quality of life for patients.

• Investigating innovative therapies for multiple sclerosis
• Testing disease‑modifying agents in amyotrophic lateral sclerosis
• Evaluating neuroprotective strategies for Parkinson's disease
• Exploring treatments for progressive supranuclear palsy

These studies aim to preserve neurological function, reduce disability, and provide new options for patients facing chronic neurodegenerative conditions.

The centre’s immunology program targets a range of autoimmune disorders, assessing novel biologics and targeted agents to modulate the immune response.

• Assessing efficacy of therapies for Sjogren’s syndrome
• Evaluating treatments for chronic inflammatory demyelinating polyneuropathy
• Studying new options for rheumatoid arthritis
• Testing interventions in polymyalgia rheumatica

The goal is to achieve better disease control, reduce flare‑ups, and improve long‑term outcomes for patients with immune‑mediated conditions.

Research in metabolic disorders concentrates on improving glycemic control, reducing cardiovascular risk, and supporting weight management.

• Investigating novel agents for type 2 diabetes
• Exploring therapies that protect pancreatic function in type 1 diabetes
• Evaluating treatments to lower triglyceride levels and obesity‑related complications
• Studying drugs that prevent heart‑failure events in patients with cardiovascular disease

These trials seek to enhance metabolic health, limit disease complications, and provide new therapeutic choices for at‑risk populations.

The site conducts studies aimed at improving outcomes for chronic lung conditions and vaccine‑related research.

• Testing new inhaled combinations for chronic obstructive pulmonary disease
• Evaluating therapies for severe asthma
• Assessing vaccine efficacy against influenza in high‑risk groups
• Investigating preventive strategies for respiratory syncytial virus in older adults

The purpose of these studies is to reduce exacerbations, improve lung function, and strengthen protection against viral infections.

Mental health research at the centre focuses on innovative pharmacologic and non‑pharmacologic approaches to treat mood disorders and addiction.

• Evaluating adjunctive agents for treatment‑resistant major depressive disorder
• Testing new medications for manic episodes in bipolar I disorder
• Studying immunomodulatory therapy for schizophrenia spectrum disorder
• Assessing adjunct treatments to improve outcomes in opioid use disorder

These trials aim to alleviate symptoms, prevent relapse, and offer safer, more effective options for individuals living with psychiatric and addictive illnesses.

Oncology research at the site explores cutting‑edge cellular therapies and targeted drugs for solid tumors.

• Investigating CAR‑T cell approaches for tumor antigens
• Evaluating novel immunotherapies combined with RNA‑based vaccines
• Studying safety and efficacy of targeted agents in advanced solid cancers

The objective is to enhance anti‑tumor immunity, improve response rates, and expand treatment options for patients with hard‑to‑treat cancers.